Ospedale Generale Provinciale Di Macerata

The oncology unit at Ospedale Generale Provinciale Di Macerata focuses on advancing treatment for non‑muscle invasive bladder cancer, especially in patients who have limited response to standard BCG therapy. Current trials aim to improve event‑free survival by testing novel immunotherapy combinations and alternative intravesical agents.

• Evaluating the efficacy of a new checkpoint inhibitor combined with BCG in high‑risk disease
• Measuring complete response rates in BCG‑unresponsive carcinoma in situ
• Comparing intravesical chemotherapy alternatives for patients ineligible for radical cystectomy
• Monitoring minimal residual disease using circulating tumor DNA as a prognostic tool

These studies seek to expand therapeutic options for bladder cancer patients and may set new standards for intravesical treatment strategies.

Research at the site covers a wide spectrum of breast cancer subtypes, from hormone‑receptor positive disease to aggressive triple‑negative breast cancer. Trials are designed to refine the timing of chemotherapy and endocrine therapy, as well as to test innovative antibody‑drug conjugates and targeted oral agents.

• Comparing neoadjuvant Dato‑DXd plus durvalumab with standard pembrolizumab‑based regimens
• Assessing sequential versus concurrent administration of chemotherapy and aromatase inhibitors in early disease
• Testing capivasertib combined with fulvestrant against placebo in HR‑positive, HER2‑negative advanced cancer
• Evaluating elacestrant versus standard endocrine therapy in node‑positive, estrogen‑receptor positive early breast cancer

The goal is to identify more effective and personalized treatment pathways that reduce recurrence and improve survival across breast cancer populations.

The department conducts extensive studies on clear cell renal cell carcinoma, targeting both metastatic and locally advanced stages. Current investigations explore intensified targeted therapy after immunotherapy and the impact of surgical timing on outcomes.

• Intensifying axitinib after nivolumab plus ipilimumab induction in metastatic disease
• Evaluating deferred cytoreductive nephrectomy combined with anti‑PD‑1 based regimens
• Comparing casdatifan plus cabozantinib versus placebo plus cabozantinib in advanced RCC
• Investigating pembrolizumab’s effect on progression in oligometastatic patients eligible for surgery or radiotherapy

These trials aim to improve survival and define optimal sequencing of immunotherapy, targeted agents, and surgery for kidney cancer patients.

Studies at the hospital address advanced non‑small‑cell lung cancer, including tumors with EGFR mutations. Research seeks to determine the best first‑line systemic options, whether immunotherapy alone, combined with anti‑angiogenic agents, or targeted tyrosine‑kinase inhibitors.

• Comparing atezolizumab alone versus atezolizumab plus bevacizumab in PD‑L1 high disease
• Sequencing dacomitinib and osimertinib in patients with classical or uncommon EGFR mutations
• Assessing efficacy of first‑line immunotherapy in EGFR‑mutated NSCLC with controlled brain metastases
• Evaluating overall survival benefits of adding bevacizumab to checkpoint inhibition

The trials aim to clarify optimal therapeutic pathways, enhancing response rates and extending survival for lung cancer patients.

The oncology team investigates treatment strategies for urothelial carcinoma, focusing on molecular predictors such as DDR gene alterations and novel antibody‑drug conjugates like sacituzumab govitecan. Research evaluates both platinum‑based chemotherapy response and targeted agents in advanced disease.

• Correlating DDR gene status with response to platinum chemotherapy
• Comparing sacituzumab govitecan to physician‑choice chemotherapy in metastatic urothelial cancer
• Assessing progression‑free survival of standard regimens versus experimental combinations
• Exploring biomarkers that predict benefit from immunotherapy in urothelial tumors

These investigations strive to personalize therapy and improve outcomes for patients with bladder and upper‑tract urothelial cancers.

Clinical research also encompasses metastatic castration‑resistant prostate cancer and multiple myeloma in patients unsuitable for transplant. Trials compare chemotherapy agents, androgen‑receptor targeted therapies, and novel monoclonal antibody combinations to establish superior efficacy and safety.

• Comparing docetaxel with abiraterone or enzalutamide as first‑line therapy in high‑risk prostate cancer
• Evaluating VMP versus lenalidomide‑dexamethasone regimens with or without daratumumab in transplant‑ineligible myeloma
• Investigating progression‑free survival of combination therapies in BRCA‑negative prostate cancer
• Monitoring overall survival benefits of adding daratumumab to standard myeloma treatment

The objective is to refine treatment algorithms, offering more effective options for patients with advanced prostate cancer and multiple myeloma.